Comparison of Nifedipine Alone and With Diltiazem or Verapamil in Hypertension
- 1 July 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 28 (1) , 109-114
- https://doi.org/10.1161/01.hyp.28.1.109
Abstract
Receptor binding studies suggest that combinations of calcium channel blockers may result in either enhanced or diminished pharmacological effects, but clinical data in hypertension are incomplete. In this study, we compared blood pressure reductions using nifedipine alone, nifedipine plus diltiazem, and nifedipine plus verapamil and determined whether combinations alter nifedipine pharmacokinetics. After determination of baseline blood pressures, 16 subjects with essential hypertension (12 men, 4 women; mean age, 48 years) received 30 mg/d open-label, sustained release nifedipine for 2 weeks. If still hypertensive (n=16), they were randomized (double-blind) to receive either additional sustained release diltiazem or sustained release verapamil, both 180 mg/d, for 2 weeks and were then crossed-over for the final 2 weeks of the study. All medications were once-daily, extended-release formulations. Blood pressures and nifedipine plasma concentrations were measured during the final day of each treatment. Overall, each combination lowered mean systolic and diastolic pressures more than nifedipine alone. Mean supine diastolic pressures were significantly lower at 8 hours (77.6 versus 84.6 mm Hg, P =.001) and 12 hours (81.5 versus 87.1 mm Hg, P =.04) with nifedipine plus diltiazem than nifedipine plus verapamil. Mean nifedipine concentrations were inversely correlated with mean blood pressures. Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng·h/mL, P =.026), with each greater than nifedipine alone (957 ng·h/mL). Nifedipine plus diltiazem had a greater antihypertensive effect than nifedipine plus verapamil. Diltiazem caused greater increases in nifedipine plasma concentrations than did verapamil. These data suggest that combined calcium channel blockers result in additive antihypertensive effects, perhaps because of a pharmacokinetic interaction.Keywords
This publication has 20 references indexed in Scilit:
- Calcium Antagonists Should Continue to Be Used for First-Line Treatment of HypertensionArchives of internal medicine (1960), 1995
- Dihydropyridine calcium antagonists and the troughJournal Of Hypertension, 1994
- The Influence of Pretreatment Periods with Diltiazem on Nifedipine KineticsThe Journal of Clinical Pharmacology, 1993
- Pharmacokinetic Interactions with Calcium Channel Antagonists (Part I)1Clinical Pharmacokinetics, 1991
- Antihypertensive Effects of a New Sustained‐Release Formulation of NifedipineThe Journal of Clinical Pharmacology, 1990
- A Double-Blind, Randomized, Crossover Comparison of Equivalent (by Weight) Oral Doses of Verapamil and Diltiazem in Patients with Mild to Moderate HypertensionJournal of Cardiovascular Pharmacology, 1989
- Differential cardiovascular effects of calcium channel blocking agents: Potential mechanismsThe American Journal of Cardiology, 1982
- Diltiazem enhancement of [3H]nitrendipine binding to calcium channel associated drug receptor sites in rat brain synaptosomesBiochemical and Biophysical Research Communications, 1982
- The binding of [3H]nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of ratsLife Sciences, 1982
- Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazemThe American Journal of Cardiology, 1980